Vyant Bio (NASDAQ:VYNT – Get Rating) had its price objective lowered by equities researchers at HC Wainwright to $3.00 in a research note issued on Tuesday, Stock Target Advisor reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 338.34% from the stock’s current […]
Vyant Bio (NASDAQ:VYNT – Get Rating) will be releasing its earnings data before the market opens on Wednesday, March 30th. Analysts expect Vyant Bio to post earnings of ($0.16) per share for the quarter. Shares of VYNT stock opened at $1.16 on Tuesday. The stock has a fifty day moving average of $1.11 and a […]
Vyant Bio (NASDAQ:VYNT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel […]
Zacks Investment Research upgraded shares of Vyant Bio (NASDAQ:VYNT – Get Rating) from a sell rating to a hold rating in a research report report published on Thursday morning, Zacks.com reports. According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence […]